The Global Single-channel DBS Parkinson's Disease Market is witnessing significant growth and is projected to reach a value of USD 4.9 billion by 2032, with a revenue compound annual growth rate (CAGR) of 8.5% during the forecast period. This growth can be attributed to the increasing aging population worldwide and the rising prevalence of Parkinson's disease. Parkinson's disease, a chronic and degenerative movement disorder, affects millions of people globally, with a higher prevalence in developed countries. The market revenue is expected to be driven by the growing prevalence of Parkinson's disease and the limited efficacy of existing treatments.
Deep Brain Stimulation for Parkinson's disease is a neurosurgical procedure that involves implanting electrodes in specific regions of the brain to control abnormal impulses and improve motor functions in patients. The market growth is fueled by the increasing demand for less invasive surgeries and innovative DBS technology. The precise placement of electrodes in the brain, made possible by advanced imaging techniques such as CT and MRI, is also contributing to market growth. Furthermore, there are ongoing research and development efforts to develop novel DBS systems and enhance the effectiveness and safety of the procedure. Several clinical trials are being conducted to explore the potential of DBS in treating various neurological conditions, including epilepsy, depression, and obsessive-compulsive disorder.
However, there are certain factors that may hinder market expansion, such as the high cost of DBS procedures, the lack of reimbursement policies in developing countries, and the possibility of procedure-related complications. The COVID-19 pandemic has also had an impact on the market, with temporary suspension of elective procedures and disruptions in the supply chain.
Request Sample of These Report @
https://www.reportsanddata.com/download-free-sample/6352
According to the National Institutes of Health, deep brain stimulation has proven to be an effective treatment for Parkinson's disease, reducing symptoms such as tremor, stiffness, and difficulty in walking. In the United States, approximately 60,000 people are estimated to be living with DBS implants. Government regulations play a crucial role in the market. The U.S. Food and Drug Administration (FDA) has approved several DBS devices for Parkinson's disease treatment, and Medicare provides coverage for DBS therapy for eligible patients. The Centers for Medicare and Medicaid Services have issued reimbursement guidelines to ensure appropriate coverage and payment policies.
In the United Kingdom, the National Institute for Health and Care Excellence (NICE) recommends DBS as a treatment option for advanced Parkinson's disease. The European Commission has established guidelines for the safety and performance of medical devices, including DBS systems. In terms of product types, the market is categorized into Single-channel DBS, Dual-channel DBS, and Others. Single-channel DBS, with its efficiency and cost-effectiveness, accounted for a significant portion of the market revenue in 2021. Dual-channel DBS is expected to register the fastest revenue growth during the forecast period, driven by its more focused stimulation and greater effectiveness in controlling Parkinson's disease symptoms.
To know Latest Insights of These Report @
https://www.reportsanddata.com/request-latest-insight/6352
The market is also segmented by end-use, including Hospitals, Ambulatory Surgery Centers, and others. Hospitals currently hold the largest revenue share due to their access to trained medical personnel, advanced facilities, and comprehensive patient care services. Ambulatory Surgery Centers are expected to grow at the fastest pace, driven by the increasing preference for outpatient procedures that are less invasive and cost-effective.
Geographically, North America leads the market, attributed to its growing elderly population and the rising awareness of DBS therapy's benefits in treating Parkinson's disease. Europe is also a significant market, driven by the high prevalence of Parkinson's disease and a robust healthcare system. Asia Pacific is expected to witness the fastest revenue growth, fueled by the increasing aging population, rising prevalence of Parkinson's disease, and collaborations between local and international companies for the development and commercialization of DBS therapy.
Key Players Operating in Single-channel DBS Parkinson’s Disease Market
- Medtronic
- Boston Scientific Corporation
- Jude Medical
- Abbott Laboratories
- Aleva Neurotherapeutics
- Sapiens Neuro
- SceneRay Corporation
- Beijing PINS Medical Co. Ltd.
- Magstim
- Fisher Wallace
The global Single-channel DBS Parkinson’s Disease Market has been segmented as follows:
By Product Type Outlook:
- Single-channel DBS
- Dual-channel DBS
- Others
By End-use Outlook:
- Hospitals
- Ambulatory Surgery Centers
- Others
Regional Outlook:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Country Scope:
- U.S.
- Canada
- U.K.
- Germany
- France
- BENELUX (Belgium, Netherlands, Luxembourg)
- China
- India
- Japan
- South Korea
- Brazil
- Saudi Arabia
- UAE (United Arab Emirates)
- Turkey
Request a customization of the report @
https://www.reportsanddata.com/request-customization-form/6352
Thank you for reading global Single-channel DBS Parkinson’s Disease Market report. We also offer customized research reports as per client requirement. Kindly contact us to know more about the feature and our team will provide you a well-curated report in the stipulated time.
About Us:
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact Us:
John W
Head of Business Development
Reports And Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
LinkedIn | Twitter | Blogs | Insights
https://www.sinp.msu.ru/ru/ext_link?url=https://www.reportsanddata.com
https://content.iospress.com/LOGOUT?dest=https://www.reportsanddata.com
https://spotlight.radiopublic.com/images/thumbnail?url=https://www.reportsanddata.com